The aryl hydrocarbon receptor directly regulates expression of the potent mitogen epiregulin

Toxicological Sciences

Volumn 89, Issue 1, 2006, Pages 75-82

  Patel, Rushang D ^a   Kim, Dae Joon ^a   Peters, Jeffrey M ^a   Perdew, Gary H ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

AhR; Epiregulin; Growth factor; TCDD; Transcription

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; EPIREGULIN; LUCIFERASE; MITOGENIC AGENT; NUCLEOTIDE; RECEPTOR ANTIBODY;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL GROWTH; CHROMATIN; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; IMMUNOPRECIPITATION; KERATINOCYTE; MOUSE; NEWBORN; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; TUMOR PROMOTION; UPREGULATION;

ANIMALS; ANIMALS, NEWBORN; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, VIRAL; CHROMATIN IMMUNOPRECIPITATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; HEPATOCYTES; KERATINOCYTES; MICE; MICE, INBRED C57BL; MITOGENS; NIH 3T3 CELLS; RECEPTORS, ARYL HYDROCARBON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRACHLORODIBENZODIOXIN; TRANSCRIPTION, GENETIC; UP-REGULATION;

ANIMALIA; RODENTIA;

EID: 29544447365     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfi344     Document Type: Article

References (45)

1. Andersson, P., McGuire, J., Rubio, C., Gradin, K., Whitelaw, M. L., Pettersson, S., Hanberg, A., and Poellinger, L. (2002). A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc. Natl. Acad. Sci. U.S.A. 99, 9990-9995.
2. Baba, I., Shirasawa, S., Iwamoto, R., Okumura, K., Tsunoda, T., Nishioka, M., Fukuyama, K., Yamamoto, K., Mekada, E., and Sasazuki, T. (2000). Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. Cancer Res. 60, 6886-6889.
3. Benedict, J. C., Lin, T. M., Loeffler, I. K., Peterson, R. E., and Flaws, J. A. (2000). Physiological role of the aryl hydrocarbon receptor in mouse ovary development. Toxicol. Sci. 56, 382-388.
4. Carlson, D. B., and Perdew, G. H. (2002). A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of Ah receptor interacting proteins. J. Biochem. Mol. Toxicol. 16, 317-325.
5. Chou, J. Y. (1985). Establishment of rat fetal liver lines and characterization of their metabolic and hormonal properties: Use of temperature-sensitive SV40 virus. Methods Enzymol. 109, 385-396.
6. Cole, P., Trichopoulos, D., Pastides, H., Starr, T., and Mandel, J. S. (2003). Dioxin and cancer: A critical review. Regul. Toxicol. Pharmacol. 38, 378-388.
7. Denison, M. S., Pandini, A., Nagy, S. R., Baldwin, E. P., and Bonati, L. (2002). Ligand binding and activation of the Ah receptor. Chem. Biol. Interact. 141, 3-24.
8. Dlugosz, A. A., Glick, A. B., Tennenbaum, T., Weinberg, W. C., and Yuspa, S. H. (1995). Isolation and utilization of epidermal keratinocytes for oncogene research. Methods Enzymol. 254, 3-20.
9. Dragan, Y. P., and Schrenk, D. (2000). Animal studies addressing the carcinogenicity of TCDD (or related compounds) with an emphasis on tumour promotion. Food Addit. Contam. 17, 289-302.
10. Dunson, D. B., Haseman, J. K., van Birgelen, A. P., Stasiewicz, S., and Tennant, R. W. (2000). Statistical analysis of skin tumor data from Tg.AC mouse bioassays. Toxicol. Sci. 55, 293-302.
11. Elizondo, G., Fernandez-Salguero, P., Sheikh, M. S., Kim, G. Y., Fornace, A. J., Lee, K. S., and Gonzalez, F. J. (2000). Altered cell cycle control at the G(2)/M phases in aryl hydrocarbon receptor-null embryo fibroblast. Mol. Pharmacol. 57, 1056-1063.
12. Fernandez-Salguero, P., Pineau, T., Hilbert, D. M., McPhail, T., Lee, S. S., Kimura, S., Nebert, D. W., Rudikoff, S., Ward, J. M., and Gonzalez, F. J. (1995). Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 268, 722-726.
13. Fernandez-Salguero, P. M., Ward, J. M., Sundberg, J. P., and Gonzalez, F. J. (1997). Lesions of aryl-hydrocarbon receptor-deficient mice. Vet. Pathol. 34, 605-614.
14. Freimann, S., Ben-Ami, I., Hirsh, L., Dantes, A., Halperin, R., and Amsterdam, A. (2004). Drug development for ovarian hyper-stimulation and anti-cancer treatment: Blocking of gonadotropin signaling for epiregulin and amphiregulin biosynthesis. Biochem. Pharmacol. 68, 989-996.
15. Ge, N. L., and Elferink, C. J. (1998). A direct interaction between the aryl hydrocarbon receptor and retinoblastoma protein. Linking dioxin signaling to the cell cycle. J. Biol. Chem. 273, 22708-22713.
16. Harris, R. C., Chung, E., and Coffey, R. J. (2003). EGF receptor ligands. Exp. Cell Res. 284, 2-13.
17. Heid, S. E., Walker, M. K., and Swanson, H. I. (2001). Correlation of cardiotoxicity mediated by halogenated aromatic hydrocarbons to aryl hydrocarbon receptor activation. Toxicol. Sci. 61, 187-196.
18. IARC (1997). IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Polychlorinated Dibenzo-Para-Dioxins and Polychlorinated Dibenzofurans. Lyon, France, 4-11 February 1997. IARC Monogr. Eval. Carcinog. Risks Hum. 69, 1-631.
19. Kobayashi, A., Sogawa, K., and Fujii-Kuriyama, Y. (1996). Cooperative interaction between AhR.Arnt and Spl for the drug-inducible expression of CYP1A1 gene. J. Biol. Chem. 271, 12310-12316.
20. Komurasaki, T., Toyoda, H., Uchida, D., and Nemoto, N. (2002). Mechanism of growth promoting activity of epiregulin in primary cultures of rat hepatocytes. Growth Factors 20, 61-69.
21. Koo, B. H., and Kim, D. S. (2003). Factor Xa induces mitogenesis of vascular smooth muscle cells via autocrine production of epiregulin. J. Biol. Chem. 278, 52578-52586.
22. Lorenzen, A., Kennedy, S. W., Bastien, L. J., and Hahn, M. E. (1997). Halogenated aromatic hydrocarbon-mediated porphyrin accumulation and induction of cytochrome P4501A in chicken embryo hepatocytes. Biochem. Pharmacol. 53, 373-384.
23. Lund, A. K., Goens, M. B., Kanagy, N. L., and Walker, M. K. (2003). Cardiac hypertrophy in aryl hydrocarbon receptor null mice is correlated with elevated angiotensin II, endothelin-1, and mean arterial blood pressure. Toxicol. Appl. Pharmacol. 193, 177-187.
24. Moennikes, O., Loeppen, S., Buchmann, A., Andersson, P., Ittrich, C., Poellinger, L., and Schwarz, M. (2004). A constitutively active dioxin/ aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res. 64, 4707-4710.
25. Murray, I. A., Reen, R. K., Leathery, N., Ramadoss, P., Bonati, L., Gonzalez, F. J., Peters, J. M., and Perdew G. H. (in press). Evidence that ligand binding is a key determinant of Ah receptor-mediated transcriptional activity. Arch. Biochem. Biophys.
26. Nebert, D. W., Puga, A., and Vasiliou, V. (1993). Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer, and signal transduction. Ann. N. Y. Acad. Sci. 685, 624-640.
27. Nebert, D. W., Roe, A. L., Dieter, M. Z., Solis, W. A., Yang, Y., and Dalton, T. P. (2000). Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem. Pharmacol. 59, 65-85.
28. Petrulis, J. R., and Perdew, G. H. (2002). The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem. Biol. Interact. 141, 25-40.
29. Poland, A., Palen, D., and Glover, E. (1982). Tumour promotion by TCDD in skin of HRS/J hairless mice. Nature 300, 271-273.
30. Sato, K., Nakamura, T., Mizuguchi, M., Miura, K., Tada, M., Aizawa, T., Gomi, T., Miyamoto, K., and Kawano, K. (2003). Solution structure of epiregulin and the effect of its C-terminal domain for receptor binding affinity. FEBS Lett. 553, 232-238.
31. Schmidt, J. V., Su, G. H., Reddy, J. K., Simon, M. C., and Bradfield, C. A. (1996). Characterization of a murine Ahr null allele: Involvement of the Ah receptor in hepatic growth and development. Proc. Natl. Acad. Sci. U.S.A. 93, 6731-6736.
32. Sekiguchi, T., Mizutani, T., Yamada, K., Kajitani, T., Yazawa, T., Yoshino, M., and Miyamoto, K. (2004). Expression of epiregulin and amphiregulin in the rat ovary. J. Mol. Endocrinol. 33, 281-291.
33. Sekiguchi, T., Mizutani, T., Yamada, K., Yazawa, T., Kawata, H., Yoshino, M., Kajitani, T., Kameda, T., Minegishi, T., and Miyamoto, K. (2002). Transcriptional regulation of the epiregulin gene in the rat ovary. Endocrinology 143, 4718-4729.
34. Shelly, M., Pinkas-Kramarski, R., Guarino, B. C., Waterman, H., Wang, L. M., Lyass, L., Alimandi, M., Kuo, A., Bacus, S. S., Pierce, J. H., Andrews, G. C., and Yarden, Y. (1998). Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J. Biol. Chem. 273, 10496-10505.
35. Shimizu, Y., Nakatsuru, Y., Ichinose, M., Takahashi, Y., Kume, H., Mimura, J., Fujii-Kuriyama, Y., and Ishikawa, T. (2000). Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. U.S.A. 97, 779-782.
36. Shirakata, Y., Komurasaki, T., Toyoda, H., Hanakawa, Y., Yamasaki, K., Tokumaru, S., Sayama, K., and Hashimoto, K. (2000). Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes. J. Biol. Chem. 275, 5748-5753.
37. Spencer, V. A., Sun, J. M., Li, L., and Davie, J. R. (2003). Chromatin immunoprecipitation: A tool for studying histone acetylation and transcription factor binding. Methods 31, 67-75.
38. Steenland, K., Bertazzi, P., Baccarelli, A., and Kogevinas, M. (2004). Dioxin revisited: Developments since the 1997 IARC classification of dioxin as a human carcinogen. Environ. Health Perspect. 112, 1265-1268.
39. Strobeck, M. W., Fribourg, A. F., Puga, A., and Knudsen, E. S. (2000). Restoration of retinoblastoma mediated signaling to Cdk2 results in cell cycle arrest. Oncogene 19, 1857-1867
40. Swanson, H. I., Whitelaw, M. L., Petrulis, J. R., and Perdew, G. H. (2002). Use of [125I]4′-iodoflavone as a tool to characterize ligand-dependent differences in Ah receptor behavior. J. Biochem. Mol. Toxicol. 16, 298-310.
41. Takahashi, M., Hayashi, K., Yoshida, K., Ohkawa, Y., Komurasaki, T., Kitabatake, A., Ogawa, A., Nishida, W., Yano, M., Monden, M., et al. (2003). Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells. Circulation 108, 2524-2529.
42. Torring, N., Jorgensen, P. E., Sorensen, B. S., and Nexo, E. (2000). Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res. 20, 91-95.
43. Toyoda, H., Komurasaki, T., Uchida, D., Takayama, Y., Isobe, T., Okuyama, T., and Hanada, K. (1995). Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J. Biol. Chem. 270, 7495-7500.
44. Yamamoto, T., Akisue, T., Marui, T., Nakatani, T., Kawamoto, T., Hitora, T., Nagira, K., Fujita, I., Matsumoto, K., and Kurosaka, M. (2004). Expression of betacellulin, heparin-binding epidermal growth factor and epiregulin in human malignant fibrous histiocytoma. Anticancer Res. 24, 2007-2010.
45. Zhu, Z., Kleeff, J., Friess, H., Wang, L., Zimmermann, A., Yarden, Y., Buchler, M. W., and Korc, M. (2000). Epiregulin is up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem. Biophys. Res. Commun. 273, 1019-1024.